Format

Send to

Choose Destination
Int Surg. 2015 Jan;100(1):21-8. doi: 10.9738/INTSURG-D-14-00089.1.

Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix.

Author information

1
1 Department of Surgery, Princess Alexandra Hospital, Brisbane, Australia.

Abstract

Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is a radical but effective treatment option for select peritoneal malignancies. We sought to determine our early experience with this method for peritoneal carcinomatosis secondary to mucinous adenocarcinomas of appendiceal origin. As such, we performed a retrospective clinical study of 30 consecutive patients undergoing CRS with planned HIPEC at the Princess Alexandra Hospital, between June 2009 to December 2012, with mucinous adenocarcinomas of the appendix. CRS was performed in 30 patients, 13 received HIPEC intraoperatively and 17 received early postoperative intra-peritoneal chemotherapy (EPIC) in addition. Mean age was 52.3 years and median hospital stay was 26 days (range 12-190 days). Peritoneal cancer index scores were 0-10 in 6.7% of patients, 11-20 in 20% of patients and >20 in 73.3% of patients. Complete cytoreduction was achieved overall in 21 patients. In total, 106 complications were observed in 28 patients. Ten were grade 3-A, five were grade 3-B and one grade-5 secondary to a fatal PE on day 97. In patients who received HIPEC, there was no difference in disease-free survival (P = 0.098) or overall survival (P = 0.645) between those who received EPIC versus those who did not. This study demonstrates that satisfactory outcomes with regards to morbidity and survival can be achieved with CRS and HIPEC, at a single-centre institution with growing expertise in the technique. Our results are comparable with outcomes previously described in the international literature.

KEYWORDS:

Cytoreductive surgery; Early postoperative intraperitoneal chemotherapy; Heated intraperitoneal chemotherapy; Pseudomyxoma peritonei

PMID:
25594636
PMCID:
PMC4301290
DOI:
10.9738/INTSURG-D-14-00089.1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Allen Press, Inc. Icon for PubMed Central
Loading ...
Support Center